About Inovio Pharmaceuticals (NASDAQ:INO)
Inovio Pharmaceuticals, Inc. (Inovio) is a clinical-stage pharmaceutical company, which is involved in developing deoxyribonucleic acid (DNA) immunotherapies and vaccines focused on treating and preventing cancers and infectious diseases. The Company's DNA-based immunotherapies, in combination with its electroporation delivery devices, generates immune responses, in particular T cells, in the body to fight target diseases. It has completed, current or planned clinical programs of its SynCon immunotherapies for human papillomavirus (HPV)-caused pre-cancers and cancers, influenza, prostate cancer, breast/lung/pancreatic cancer, hepatitis C virus (HCV), hepatitis B virus (HBV), human immunodeficiency virus (HIV), Ebola, Middle East Respiratory Syndrome (MERS) and Zika virus. With its immunotherapy platform, as well as with its CELLECTRA electroporation delivery technology, it has a pipeline of pre-clinical and clinical stage products that have generated in vivo immune responses.
Industry, Sector and Symbol
Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:INO
CUSIPN/A
Phone267-440-4200
Debt
Debt-to-Equity RatioN/A
Current Ratio3.91%
Quick Ratio3.91%
Price-To-Earnings
Trailing P/E Ratio-4.26
Forward P/E Ratio-4.34
P/E GrowthN/A
Sales & Book Value
Annual Sales$42.22 million
Price / Sales9.97
Cash FlowN/A
Price / CashN/A
Book Value$1.58 per share
Price / Book2.94
Profitability
EPS (Most Recent Fiscal Year)($1.09)
Net Income$-88,200,000.00
Net Margins-208.92%
Return on Equity-66.07%
Return on Assets-50.18%
Miscellaneous
Employees280
Outstanding Shares90,700,000
Inovio Pharmaceuticals (NASDAQ:INO) Frequently Asked Questions
What is Inovio Pharmaceuticals' stock symbol?
Inovio Pharmaceuticals trades on the NASDAQ under the ticker symbol "INO."
How often does Inovio Pharmaceuticals pay dividends? What is the dividend yield for Inovio Pharmaceuticals?
Inovio Pharmaceuticals announced a monthly dividend on Thursday, September 21st. Shareholders of record on Friday, September 29th will be given a dividend of $0.069 per share on Monday, October 16th. This represents a $0.83 dividend on an annualized basis and a yield of 17.84%. The ex-dividend date is Thursday, September 28th. View Inovio Pharmaceuticals' Dividend History.
When did Inovio Pharmaceuticals' stock split? How did Inovio Pharmaceuticals' stock split work?
Shares of Inovio Pharmaceuticals reverse split before market open on Friday, June 6th 2014. The 1-4 reverse split was announced on Friday, May 23rd 2014. The number of shares owned by shareholders was adjusted after the market closes on Thursday, June 5th 2014. An investor that had 100 shares of Inovio Pharmaceuticals stock prior to the reverse split would have 25 shares after the split.
How were Inovio Pharmaceuticals' earnings last quarter?
Inovio Pharmaceuticals Inc (NASDAQ:INO) posted its earnings results on Wednesday, March, 14th. The biopharmaceutical company reported ($0.24) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.30) by $0.06. The biopharmaceutical company earned $8.80 million during the quarter, compared to the consensus estimate of $9.13 million. Inovio Pharmaceuticals had a negative return on equity of 66.07% and a negative net margin of 208.92%. Inovio Pharmaceuticals's revenue for the quarter was up 3.5% compared to the same quarter last year. During the same period last year, the company posted ($0.35) EPS. View Inovio Pharmaceuticals' Earnings History.
When is Inovio Pharmaceuticals' next earnings date?
What price target have analysts set for INO?
10 equities research analysts have issued twelve-month price targets for Inovio Pharmaceuticals' stock. Their predictions range from $8.00 to $40.00. On average, they expect Inovio Pharmaceuticals' stock price to reach $20.10 in the next year. View Analyst Ratings for Inovio Pharmaceuticals.
What are Wall Street analysts saying about Inovio Pharmaceuticals stock?
Here are some recent quotes from research analysts about Inovio Pharmaceuticals stock:
- 1. According to Zacks Investment Research, "Inovio’s progress with its lead pipeline candidate, VGX-3100, for treatment of cervical dysplasia is encouraging. We are also positive on the company’s collaboration with big pharma companies like Regeneron, AstraZeneca, and the University of Pennsylvania, as it lends Inovio with their expertise. Moreover, the company’s targeted cervical cancer market holds untapped potential. On the flip side, as the company has no approved product in its portfolio, its excessive dependence on its partners for funding the development of its pipeline candidates is concerning. Moreover, due to early/mid-stage nature of its pipeline, the candidates are several steps away from entering the market. Shares of the company have underperformed the industry in the last one year." (1/9/2018)
- 2. Maxim Group analysts commented, "Inovio announced an amended agreement with ApolloBio (NEEQ: 430187) to develop and commercialize VGX-3100 for precancerous HPV (human papillomavirus) infections and dysplasias (cervical, vulvar, anal) in Greater China (China, Hong Kong, Macao, Taiwan, potentially Korea too). Inovio will receive an upfront payment of $23M plus milestones and royalties. The deal is expected to close in 1Q18." (1/2/2018)
Who are some of Inovio Pharmaceuticals' key competitors?
Some companies that are related to Inovio Pharmaceuticals include K2M Group (KTWO), MiMedx Group (MDXG), LeMaitre Vascular (LMAT), CryoLife (CRY), Cardiovascular Systems (CSII), AtriCure (ATRC), AngioDynamics (ANGO), Cerus (CERS), Anika Therapeutics (ANIK), Tactile Systems Technology (TCMD), SurModics (SRDX), Accuray (ARAY), Utah Medical Products (UTMD), Endologix (ELGX), Antares Pharma (ATRS), GenMark Diagnostics (GNMK), Tandem Diabetes Care (TNDM) and Pulse Biosciences (PLSE).
Who are Inovio Pharmaceuticals' key executives?
Inovio Pharmaceuticals' management team includes the folowing people:
- Jong Joseph Kim Ph.D., President, Chief Executive Officer, Director (Age 48)
- Peter D. Kies, Chief Financial Officer (Age 53)
- Niranjan Y. Sardesai Ph.D., Chief Operating Officer (Age 49)
- Mark L. Bagarazzi M.D., Chief Medical Officer (Age 56)
- Avtar S. Dhillon M.D., Non-Executive Chairman of the Board (Age 56)
- George W. Bickerstaff III, Director (Age 62)
- David B. Weiner, Director (Age 61)
- Wendy L. Yarno, Director (Age 63)
- Simon X. Benito, Independent Director (Age 72)
Has Inovio Pharmaceuticals been receiving favorable news coverage?
Media stories about INO stock have trended somewhat positive recently, Accern Sentiment reports. The research group scores the sentiment of press coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Inovio Pharmaceuticals earned a coverage optimism score of 0.18 on Accern's scale. They also gave media coverage about the biopharmaceutical company an impact score of 46.79 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the next several days.
How do I buy shares of Inovio Pharmaceuticals?
Shares of INO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Inovio Pharmaceuticals' stock price today?
One share of INO stock can currently be purchased for approximately $4.64.
How big of a company is Inovio Pharmaceuticals?
Inovio Pharmaceuticals has a market capitalization of $419.95 million and generates $42.22 million in revenue each year. The biopharmaceutical company earns $-88,200,000.00 in net income (profit) each year or ($1.09) on an earnings per share basis. Inovio Pharmaceuticals employs 280 workers across the globe.
How can I contact Inovio Pharmaceuticals?
Inovio Pharmaceuticals' mailing address is 660 WEST GERMANTOWN PIKE SUITE 110, PLYMOUTH MEETING PA, 19462. The biopharmaceutical company can be reached via phone at 267-440-4200 or via email at [email protected]
MarketBeat Community Rating for Inovio Pharmaceuticals (INO)
MarketBeat's community ratings are surveys of what our community members think about Inovio Pharmaceuticals and other stocks. Vote "Outperform" if you believe INO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe INO will underperform the S&P 500 over the long term. You may vote once every thirty days.
Inovio Pharmaceuticals (NASDAQ:INO) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
10 Wall Street analysts have issued ratings and price targets for Inovio Pharmaceuticals in the last 12 months. Their average twelve-month price target is $20.10, suggesting that the stock has a possible upside of 333.19%. The high price target for INO is $40.00 and the low price target for INO is $8.00. There are currently 2 hold ratings and 8 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 2.80 | 2.80 | 2.80 | 2.80 |
| Ratings Breakdown: | 0 Sell Rating(s)
2 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
2 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
2 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
2 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $20.10 | $20.10 | $20.20 | $20.20 |
| Price Target Upside: | 333.19% upside | 302.00% upside | 351.90% upside | 223.72% upside |
Inovio Pharmaceuticals (NASDAQ:INO) Consensus Price Target History
Inovio Pharmaceuticals (NASDAQ:INO) Analyst Ratings History
Show:
(Data available from 4/21/2016 forward)
Inovio Pharmaceuticals (NASDAQ:INO) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
| 9/21/2017 | Monthly | $0.0690 | | 9/28/2017 | 9/29/2017 | 10/16/2017 |
| 8/22/2017 | Monthly | $0.0690 | | 8/29/2017 | 8/31/2017 | 9/15/2017 |
| 7/25/2017 | Monthly | $0.0690 | | 7/27/2017 | 7/31/2017 | 8/15/2017 |
| 6/23/2017 | Monthly | $0.0690 | | 6/28/2017 | 6/30/2017 | 7/17/2017 |
(Data available from 1/1/2013 forward)
Inovio Pharmaceuticals (NASDAQ INO) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 9.40%
Institutional Ownership Percentage: 31.50%
Inovio Pharmaceuticals (NASDAQ INO) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 4/16/2018 | David B Weiner | Director | Sell | 9,000 | $4.91 | $44,190.00 | 758,956 |  |
| 4/12/2018 | Jong Joseph Kim | CEO | Sell | 103,750 | $5.14 | $533,275.00 | 2,395,557 | |
| 4/12/2018 | Simon X Benito | Director | Sell | 3,750 | $5.23 | $19,612.50 | 31,548 | |
| 5/25/2017 | David B Weiner | Director | Sell | 8,000 | $8.00 | $64,000.00 | 740,956 | |
| 3/31/2017 | Jong Joseph Kim | CEO | Sell | 147,180 | $6.54 | $962,557.20 | 2,164,887 | |
| 3/27/2017 | Morton Collins | Director | Buy | 21,300 | $6.25 | $133,125.00 | 142,291 | |
| 8/29/2016 | Niranjan Sardesai | COO | Sell | 21,800 | $9.30 | $202,740.00 | 70,234 | |
| 6/28/2016 | Morton Collins | Director | Buy | 10,000 | $9.13 | $91,300.00 | 142,291 | |
| 5/18/2016 | Simon X Benito | Director | Sell | 6,250 | $10.37 | $64,812.50 | 24,048 | |
| 4/15/2016 | Morton Collins | Director | Buy | 68,400 | $9.52 | $651,168.00 | 127,291 | |
| 9/30/2015 | Niranjan Sardesai | COO | Buy | 4,000 | $5.50 | $22,000.00 | 32,000 | |
| 8/14/2015 | Simon X Benito | Director | Buy | 6,000 | $7.21 | $43,260.00 | | |
| 4/13/2015 | Angel Cabrera | Director | Buy | 8,000 | $9.53 | $76,240.00 | | |
| 10/9/2014 | Peter Kies | CFO | Buy | 3,960 | $10.10 | $39,996.00 | | |
| 8/21/2014 | Morton Collins | Director | Buy | 8,000 | $10.01 | $80,080.00 | | |
| 8/20/2014 | Morton Collins | Director | Buy | 40,600 | $9.74 | $395,444.00 | | |
| 8/12/2014 | Jong Joseph Kim | CEO | Buy | 250,000 | $9.06 | $2,265,000.00 | | |
| 8/12/2014 | Niranjan Sardesai | COO | Buy | 2,550 | $8.70 | $22,185.00 | | |
| 4/15/2014 | Jong Joseph Kim | CEO | Buy | 25,000 | $2.25 | $56,250.00 | 5,965,809 | |
| 11/13/2013 | Morton Collins | Director | Buy | 254,500 | $1.82 | $463,190.00 | 655,864 | |
| 4/16/2013 | Mark Bagarazzi | Insider | Buy | 60,000 | $0.56 | $33,600.00 | | |
| 4/2/2013 | Jong Joseph Kim | CEO | Buy | 90,000 | $0.50 | $45,000.00 | | |
| 3/22/2013 | Angel Cabrera | Director | Buy | 40,000 | $0.54 | $21,600.00 | | |
| 3/20/2013 | Jong Joseph Kim | CEO | Buy | 60,000 | $0.53 | $31,800.00 | | |
| 3/20/2013 | Niranjan Sardesai | COO | Buy | 25,000 | $0.53 | $13,250.00 | | |
| 1/15/2013 | Morton Collins | Director | Buy | 100,000 | $0.67 | $67,000.00 | | |
| 11/14/2012 | Austin W & Greenhouse Da Marxe | Major Shareholder | Sell | 622,550 | $0.53 | $329,951.50 | | |
| 8/15/2012 | Angel Cabrera | Director | Buy | 75,000 | $0.59 | $44,250.00 | | |
(Data available from 1/1/2013 forward)
Inovio Pharmaceuticals (NASDAQ INO) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | Insider Selling: Inovio Pharmaceuticals Inc (INO) Director Sells 9,000 Shares of Stock
www.americanbankingnews.com - April 19 at 7:52 PM |
| Inovio Pharmaceuticals Inc (INO) Director Sells $19,612.50 in Stock
www.americanbankingnews.com - April 13 at 7:27 PM |
| Inovio Pharmaceuticals Inc (INO) CEO Jong Joseph Kim Sells 103,750 Shares
www.americanbankingnews.com - April 13 at 7:11 PM |
 | Why Is Inovio (INO) Up 6.6% Since Its Last Earnings Report?
finance.yahoo.com - April 13 at 3:12 PM |
| Inovio Pharmaceuticals (INO) Given a $13.00 Price Target at HC Wainwright
www.americanbankingnews.com - April 12 at 11:17 AM |
 | BLCM Surges As FDA Lifts Hold, SMMT Awaits Data In Q3, GEN Exits Texas
www.nasdaq.com - April 12 at 5:15 AM |
| Inovio Pharmaceuticals (INO) PT Set at $12.00 by Maxim Group
www.americanbankingnews.com - April 11 at 11:52 PM |
 | Inovio Pharma (INO) Awarded up to $56M from CEPI
www.streetinsider.com - April 11 at 3:13 PM |
 | Inovio Awarded up to $56 Million from CEPI to Advance DNA Vaccines Against Lassa Fever and MERS
globenewswire.com - April 11 at 3:13 PM |
 | $56 million deal: Inovio secures Coalition funding for vaccine candidates
www.bizjournals.com - April 11 at 3:13 PM |
| Inovio Pharmaceuticals (INO) Given a $8.00 Price Target at Maxim Group
www.americanbankingnews.com - April 11 at 12:37 PM |
| Inovio Pharmaceuticals Inc (INO) Given Average Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - April 11 at 1:24 AM |
| Inovio Pharmaceuticals (INO) Rating Increased to Sell at ValuEngine
www.americanbankingnews.com - April 10 at 7:51 PM |
 | Inovio Pharmaceuticals (INO) Presents At H. C. Wainwright Global Life Sciences Conference - Slideshow
seekingalpha.com - April 10 at 3:01 PM |
| Inovio Pharmaceuticals (INO) Stock Rating Lowered by Zacks Investment Research
www.americanbankingnews.com - April 7 at 4:58 PM |
| HC Wainwright Analysts Give Inovio Pharmaceuticals (INO) a $13.00 Price Target
www.americanbankingnews.com - April 6 at 11:31 PM |
| Inovio Pharmaceuticals (INO) Coverage Initiated by Analysts at Royal Bank of Canada
www.americanbankingnews.com - April 6 at 4:15 PM |
| Inovio Pharmaceuticals to Present at the HC Wainwright Annual Global Life Sciences Conference
globenewswire.com - April 3 at 5:09 AM |
| Inovio Pharmaceuticals to Present at the H.C. Wainwright Annual Global Life Sciences Conference
finance.yahoo.com - April 2 at 3:13 PM |
| Inovio Pharmaceuticals' (INO) "Buy" Rating Reiterated at HC Wainwright
www.americanbankingnews.com - March 31 at 5:28 PM |
| Inovio Pharmaceuticals (INO) Upgraded by Zacks Investment Research to "Hold"
www.americanbankingnews.com - March 29 at 10:49 PM |
| Inovio Pharmaceuticals (INO) Upgraded to Sell by ValuEngine
www.americanbankingnews.com - March 26 at 5:58 PM |
| Inovio's China Partnership License Agreement Should Be Cheered - Seeking Alpha
seekingalpha.com - March 23 at 5:12 AM |
| Blog Exposure - Inovio Pharma Closed Collaboration Deal with ApolloBio to Develop and Commercialize VGX-3100 in Greater China
finance.yahoo.com - March 22 at 3:13 PM |
| Inovio Pharmaceuticals (INO) Given a $13.00 Price Target by HC Wainwright Analysts
www.americanbankingnews.com - March 21 at 1:48 PM |
| Inovio Pharma (INO) Closes Pact with ApolloBio to Develop and ... - StreetInsider.com
www.streetinsider.com - March 20 at 3:10 PM |
| Inovio Closes License and Collaboration Agreement with ApolloBio To Develop and Commercialize VGX-3100 in Greater China
finance.yahoo.com - March 20 at 3:10 PM |
| $43M deal: Inovio finalizes restructured collaboration with Chinese biopharm firm
finance.yahoo.com - March 20 at 3:10 PM |
| Inovio Pharmaceuticals Inc (INO) Given Consensus Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - March 17 at 1:52 AM |
| Maxim Group Analysts Give Inovio Pharmaceuticals (INO) a $8.00 Price Target
www.americanbankingnews.com - March 15 at 11:10 PM |
| Inovio Pharmaceuticals (INO) PT Set at $13.00 by HC Wainwright
www.americanbankingnews.com - March 15 at 10:30 PM |
| Inovio Pharmaceuticals (INO) Price Target Increased to $14.00 by Analysts at Royal Bank of Canada
www.americanbankingnews.com - March 15 at 7:42 PM |
| Inovio's (INO) Q4 Loss Narrower than Expected, Revenues Beat - Nasdaq
www.nasdaq.com - March 15 at 3:12 PM |
| Inovio's (INO) Q4 Loss Narrower than Expected, Revenues Beat
finance.yahoo.com - March 15 at 3:12 PM |
| Inovio Pharmaceuticals Reports 2017 Fourth Quarter and Year End ... - GlobeNewswire (press release)
globenewswire.com - March 15 at 5:11 AM |
| Inovio Pharmaceuticals Inc (INO) Q4 Revenue Grew 3.5% Year-Over-Year - Nasdaq
www.nasdaq.com - March 15 at 5:11 AM |
 | Inovio Pharmaceuticals Inc (INO) Q4 Revenue Grew 3.5% Year ... - Investorplace.com
investorplace.com - March 15 at 5:11 AM |
| Inovio Pharmaceuticals (INO) Raised to "Hold" at BidaskClub
www.americanbankingnews.com - March 14 at 6:39 PM |
| Inovio Pharmaceuticals Inc (INO) Q4 Revenue Grew 3.5% Year-Over-Year
investorplace.com - March 14 at 5:57 PM |
| Inovio Pharmaceuticals (INO) Issues Quarterly Earnings Results, Beats Expectations By $0.06 EPS
www.americanbankingnews.com - March 14 at 5:54 PM |
| Inovio Pharma (INO) Announces Interim Phase 1 Results for DNA Immunotherapy to Treat HBV - StreetInsider.com
www.streetinsider.com - March 14 at 3:11 PM |
 | Earnings Preview For Inovio Pharmaceuticals - Benzinga
www.benzinga.com - March 14 at 3:11 PM |
| Earnings Preview For Inovio Pharmaceuticals
finance.yahoo.com - March 14 at 3:11 PM |
| Inovio’s DNA Immunotherapy Demonstrates Immune Response Results Key in Treating Chronic Hepatitis B Infection
finance.yahoo.com - March 14 at 3:11 PM |
| Inovio Pharmaceuticals to Report Fourth Quarter and Year End 2017 Financial Results on March 14, 2018 - Nasdaq
www.nasdaq.com - March 12 at 8:15 AM |
| Inovio Pharmaceuticals to Report Fourth Quarter and Year End 2017 Financial Results on March 14, 2018
finance.yahoo.com - March 12 at 8:15 AM |
| Inovio Pharmaceuticals (INO) Stock Rating Upgraded by BidaskClub
www.americanbankingnews.com - March 11 at 4:45 PM |
| What's in the Cards for Inovio (INO) This Earnings Season? - Nasdaq
www.nasdaq.com - March 6 at 3:01 PM |
| What's in the Cards for Inovio (INO) This Earnings Season?
finance.yahoo.com - March 6 at 3:01 PM |
| Zacks: Analysts Anticipate Inovio Pharmaceuticals Inc (INO) Will Post Quarterly Sales of $7.75 Million
www.americanbankingnews.com - March 5 at 9:28 AM |
Inovio Pharmaceuticals (NASDAQ:INO) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Inovio Pharmaceuticals (NASDAQ:INO) Income Statement, Balance Sheet and Cash Flow Statement
Inovio Pharmaceuticals (NASDAQ INO) Stock Chart for Saturday, April, 21, 2018
Loading chart…
